|
|
Vaccine Detail
|
Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Primary Prostate Cancer Tissue/hTERT/Survivin mRNA-loaded Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007144
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TERT
gene engineering:
- Preparation: The treatment uses DCs pulsed with prostate-specific membrane antigen (Mohammadzadeh et al., 2018).
- Description: This is for Prostate Cancer (NCT00345293).An autologous dendritic cells (DCs) vaccine targeting prostate cancer with immunostimulating activity. The autologous DC vaccine is prepared via transfecting DCs with mRNAs extracted from primary prostate cancer tissue, and mRNAs of human telomerase reverse transcriptase (hTERT) and survivin. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against prostate cancer cells, resulting in tumor cell death. Both hTERT and survivin are essential in neoplastic growth, and are considered to be universal tumor antigens (Mohammadzadeh et al., 2018; NCIT_C95771).
|
| Host Response |
|
|
| References |
Mohammadzadeh et al., 2018: Mohammadzadeh M, Shirmohammadi M, Ghojazadeh M, Nikniaz L, Raeisi M, Aghdas SAM. Dendritic cells pulsed with prostate-specific membrane antigen in metastatic castration-resistant prostate cancer patients: a systematic review and meta-analysis. Prostate international. 2018; 6(4); 119-125. [PubMed: 30505813].
NCIT_C95771: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95771]
NCT00345293: Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer [https://clinicaltrials.gov/ct2/show/NCT00345293]
|
|
